Alberto Piperno

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2558792/publications.pdf

Version: 2024-02-01

108 papers	5,376 citations	81434 41 h-index	97045 71 g-index
109 all docs	109 docs citations	109 times ranked	4242 citing authors

#	Article	IF	Citations
1	Italian patients with hemoglobinopathies exhibit a 5â€fold increase in ageâ€standardized lethality due to SARSâ€CoVâ€2 infection. American Journal of Hematology, 2022, 97, .	2.0	7
2	Iron-mediated tissue damage in acquired ineffective erythropoiesis disease: Itâ€™s more a matter of burden or more of exposure to toxic iron form?. Leukemia Research, 2022, 114, 106792.	0.4	3
3	Prolonged exposure to welding fumes as a novel cause of systemic iron overload. Liver International, 2021, 41, 1600-1607.	1.9	11
4	Atypical phenotype in a patient with ceruloplasmin mutations in the compound heterozygous state. Meta Gene, 2021, 29, 100905.	0.3	1
5	Ceruloplasmin variants might have different effects in different iron overload disorders. Journal of Hepatology, 2021, 75, 1003-1004.	1.8	4
6	HIF1A: A Putative Modifier of Hemochromatosis. International Journal of Molecular Sciences, 2021, 22, 1245.	1.8	5
7	Identification of Novel Mutations by Targeted NGS Panel in Patients with Hyperferritinemia. Genes, 2021, 12, 1778.	1.0	3
8	New Mutations in HFE2 and TFR2 Genes Causing Non HFE-Related Hereditary Hemochromatosis. Genes, 2021, 12, 1980.	1.0	4
9	Different cortical excitability profiles in hereditary brain iron and copper accumulation. Neurological Sciences, 2020, 41, 679-685.	0.9	6
10	Ferroportin disease: A novel SLC40A1 mutation. Digestive and Liver Disease, 2020, 52, 688-690.	0.4	4
11	Hyperferritinemia and diagnosis of type 1 Gaucher disease. American Journal of Hematology, 2020, 95, 570-576.	2.0	6
12	Commentary. Clinical Chemistry, 2020, 66, 281-281.	1.5	0
13	Inherited iron overload disorders. Translational Gastroenterology and Hepatology, 2020, 5, 25-25.	1.5	72
14	Phenotypic heterogeneity in seven Italian cases of aceruloplasminemia. Parkinsonism and Related Disorders, 2018, 51, 36-42.	1.1	39
15	Therapeutic recommendations in HFE hemochromatosis for p.Cys282Tyr (C282Y/C282Y) homozygous genotype. Hepatology International, 2018, 12, 83-86.	1.9	41
16	Hepatocellular carcinoma in Gaucher disease: an international case series. Journal of Inherited Metabolic Disease, 2018, 41, 819-827.	1.7	37
17	Hepcidin regulation in a mouse model of acute hypoxia. European Journal of Haematology, 2018, 100, 636-643.	1.1	17
18	Ceruloplasmin replacement therapy ameliorates neurological symptoms in a preclinical model ofÂaceruloplasminemia. EMBO Molecular Medicine, 2018, 10, 91-106.	3.3	48

#	Article	IF	Citations
19	Aceruloplasminemia: Waiting for an Efficient Therapy. Frontiers in Neuroscience, 2018, 12, 903.	1.4	36
20	A severe hemojuvelin mutation leading to late onset of HFE2 -hemochromatosis. Digestive and Liver Disease, 2018, 50, 859-862.	0.4	9
21	Unexplained isolated hyperferritinemia without iron overload. American Journal of Hematology, 2017, 92, 338-343.	2.0	7
22	Novel mutation in the Transferrin receptor-2 in a patient with Hereditary Hemochromatosis type 3. Meta Gene, 2017, 14, 30-32.	0.3	1
23	GNPAT rs11558492 is not a Major Modifier of Iron Status: Study of Italian Hemochromatosis Patients and Blood Donors. Annals of Hepatology, 2017, 16, 451-456.	0.6	12
24	GNPAT rs11558492 is not a Major Modifier of Iron Status: Study of Italian Hemochromatosis Patients and Blood Donors. Annals of Hepatology, 2017, 16, 451-456.	0.6	10
25	MYELODYSPLASTIC SYNDROMES AND IRON CHELATION THERAPY. Mediterranean Journal of Hematology and Infectious Diseases, 2016, 9, e2017021.	0.5	13
26	Proprotein convertase 7 rs236918 associated with liver fibrosis in Italian patients with HFEâ€related hemochromatosis. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 1342-1348.	1.4	15
27	Does aceruloplasminemia modulate iron phenotype in thalassemia intermedia?. Blood Cells, Molecules, and Diseases, 2016, 57, 112-114.	0.6	6
28	Alterations in sympathetic nerve traffic in genetic haemochromatosis before and after iron depletion therapy: a microneurographic study. European Heart Journal, 2016, 37, 988-995.	1.0	10
29	Transferrin receptor 2 mutations in patients with juvenile hemochromatosis phenotype. American Journal of Hematology, 2015, 90, E226-7.	2.0	9
30	Genome-wide association study identifies TF as a significant modifier gene of iron metabolism in HFE hemochromatosis. Journal of Hepatology, 2015, 62, 664-672.	1.8	62
31	Iron chelation with deferasirox in a patient with de-novo ferroportin mutation. Journal of Trace Elements in Medicine and Biology, 2015, 30, 1-3.	1.5	11
32	Movement disorders and brain iron overload in a new subtype of aceruloplasminemia. Parkinsonism and Related Disorders, 2015, 21, 658-660.	1.1	10
33	Simultaneous liver iron and fat measures by magnetic resonance imaging in patients with hyperferritinemia. Scandinavian Journal of Gastroenterology, 2015, 50, 429-438.	0.6	25
34	Changes in 24 h ambulatory blood pressure and effects of angiotensin II receptor blockade during acute and prolonged high-altitude exposure: a randomized clinical trial. European Heart Journal, 2014, 35, 3113-3122.	1.0	97
35	Circulating factors are involved in hypoxia-induced hepcidin suppression. Blood Cells, Molecules, and Diseases, 2014, 53, 204-210.	0.6	20
36	Olfactory impairment and pathology in neurodegenerative disorders with brain iron accumulation. Acta Neuropathologica, 2013, 126, 151-153.	3.9	9

#	Article	IF	Citations
37	Molecular diagnosis of hemochromatosis. Expert Opinion on Medical Diagnostics, 2013, 7, 161-177.	1.6	20
38	Modulation of urinary peptidome in humans exposed to high altitude hypoxia. Molecular BioSystems, 2012, 8, 959-966.	2.9	13
39	Faecal occult blood test and iron deficiency anaemia. Digestive and Liver Disease, 2012, 44, 625.	0.4	3
40	Hepcidin Expression in Iron Overload Diseases Is Variably Modulated by Circulating Factors. PLoS ONE, 2012, 7, e36425.	1.1	22
41	CYBRD1 as a modifier gene that modulates iron phenotype in HFE p.C282Y homozygous patients. Haematologica, 2012, 97, 1818-1825.	1.7	34
42	Patatin-like phospholipase domain containing-3gene I148M polymorphism, steatosis, and liver damage in hereditary hemochromatosis. World Journal of Gastroenterology, 2012, 18, 2813.	1.4	50
43	Modulation of hepcidin production during hypoxia-induced erythropoiesis in humans in vivo: data from the HIGHCARE project. Blood, 2011, 117, 2953-2959.	0.6	128
44	Hepcidin response to acute iron intake and chronic iron loading in dysmetabolic iron overload syndrome. Liver International, 2011, 31, 994-1000.	1.9	24
45	Progressive supranuclear palsyâ€like phenotype caused by progranulin p.Thr272fs mutation. Movement Disorders, 2011, 26, 1964-1966.	2.2	20
46	A time course of hepcidin response to iron challenge in patients with HFE and TFR2 hemochromatosis. Haematologica, 2011, 96, 500-506.	1.7	70
47	Index Measured at an Intermediate Altitude to Predict Impending Acute Mountain Sickness. Medicine and Science in Sports and Exercise, 2011, 43, 1811-1818.	0.2	24
48	Patients with Chronic Hepatitis C May be More Sensitive to Iron Hepatotoxicity than Patients with HFE-Hemochromatosis. Internal Medicine, 2010, 49, 2371-2377.	0.3	14
49	Measurement of serum hepcidin-25 levels as a potential test for diagnosing hemochromatosis and related disorders. Journal of Gastroenterology, 2010, 45, 1163-1171.	2.3	56
50	Hemochromatosis in Italy in the last 30 years: Role of genetic and acquired factors. Hepatology, 2010, 51, 501-510.	3.6	35
51	A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis. Hepatology, 2010, 52, 1671-1779.	3.6	103
52	Genetic and metabolic factors are associated with increased hepatic iron stores in a selected population of p.Cys282Tyr heterozygotes. Blood Cells, Molecules, and Diseases, 2010, 44, 159-163.	0.6	12
53	Iron metabolism in thalassemia and sickle cell disease. Mediterranean Journal of Hematology and Infectious Diseases, 2009, 1, e2009006.	0.5	41
54	Expression of hepcidin and other iron-related genes in type 3 hemochromatosis due to a novel mutation in transferrin receptor-2. Haematologica, 2009, 94, 276-279.	1.7	42

#	Article	IF	Citations
55	Higher Than Expected Progranulin Mutation Rate in a Case Series of Italian FTLD Patients. Alzheimer Disease and Associated Disorders, 2009, 23, 301.	0.6	11
56	Homozygous deletion of HFE: the Sardinian hemochromatosis?. Blood, 2009, 113, 3886-3886.	0.6	12
57	Hepcidin modulation in human diseases: From research to clinic. World Journal of Gastroenterology, 2009, 15, 538.	1.4	92
58	Novel mutations of the ferroportin gene (SLC40A1): analysis of 56 consecutive patients with unexplained iron overload. Clinical Genetics, 2008, 73, 171-178.	1.0	29
59	Reduced expression of hepcidin in patients with myelodysplastic syndrome and myelofibrosis: the causes might be more heterogeneous than in thalassaemia. British Journal of Haematology, 2008, 143, 746-747.	1.2	4
60	Hepcidin and iron-related gene expression in subjects with Dysmetabolic Hepatic Iron Overload. Journal of Hepatology, 2008, 49, 123-133.	1.8	92
61	Measurement of urinary hepcidin levels by SELDI-TOF-MS in HFE-hemochromatosis. Blood Cells, Molecules, and Diseases, 2008, 40, 347-352.	0.6	54
62	Revaluation of clinical and histological criteria for diagnosis of dysmetabolic iron overload syndrome. World Journal of Gastroenterology, 2008, 14, 4745.	1.4	57
63	Effects of plasma transfusion on hepcidin production in human congenital hypotransferrinemia. Haematologica, 2007, 92, 1407-1410.	1.7	41
64	Blunted hepcidin response to oral iron challenge in HFE-related hemochromatosis. Blood, 2007, 110, 4096-4100.	0.6	139
65	Ferritin, metabolic syndrome and NAFLD: Elective attractions and dangerous liaisons. Journal of Hepatology, 2007, 46, 549-552.	1.8	59
66	Î±1-Antitrypsin mutations in NAFLD: High prevalence and association with altered iron metabolism but not with liver damage. Hepatology, 2006, 44, 857-864.	3.6	88
67	Iron Accumulation in Chronic Hepatitis C. American Journal of Clinical Pathology, 2005, 124, 846-853.	0.4	34
68	Iron accumulation in chronic hepatitis C: relation of hepatic iron distribution, HFE genotype, and disease course. American Journal of Clinical Pathology, 2005, 124, 846-53.	0.4	11
69	Effects of venesections and restricted diet in patients with the insulin-resistance hepatic iron overload syndrome. Liver International, 2004, 24, 471-476.	1.9	44
70	Type 3 hemochromatosis and Î² -thalassemia trait. European Journal of Haematology, 2004, 72, 370-374.	1.1	25
71	Screening hepcidin for mutations in juvenile hemochromatosis: identification of a new mutation (C70R). Blood, 2004, 103, 2407-2409.	0.6	80
72	Spectrum of hemojuvelin gene mutations in 1q-linked juvenile hemochromatosis. Blood, 2004, 103, 4317-4321.	0.6	167

#	Article	IF	Citations
73	Homozygosity for transferrin receptor-2 Y250X mutation induces early iron overload. Haematologica, 2004, 89, 359-60.	1.7	34
74	Effects of Hematocrit Changes on Flow-Mediated and Metabolic Vasodilation in Humans. Hypertension, 2002, 40, 74-77.	1.3	36
75	Increased serum ferritin is common in men with essential hypertension. Journal of Hypertension, 2002, 20, 1513-1518.	0.3	150
76	Natural history of juvenile haemochromatosis. British Journal of Haematology, 2002, 117, 973-979.	1.2	145
77	New mutations inactivating transferrin receptor 2 in hemochromatosis type 3. Blood, 2001, 97, 2555-2560.	0.6	232
78	Clinical, biochemical and molecular findings in a series of families with hereditary hyperferritinaemia-cataract syndrome. British Journal of Haematology, 2001, 115, 334-340.	1.2	61
79	Haemochromatosis in patients with Î²â€thalassaemia trait. British Journal of Haematology, 2000, 111, 908-914.	1.2	37
80	Radial artery wall alterations in genetic hemochromatosis before and after iron depletion therapy. Hepatology, 2000, 32, 569-573.	3.6	34
81	Expression of iron overload in hemochromatosis. , 2000, , 177-184.		4
82	Two novel nonsense mutations of HFE gene in five unrelated Italian patients with hemochromatosis. Gastroenterology, 2000, 119, 441-445.	0.6	92
83	Insulin resistance influences iron metabolism and hepatic steatosis in type II diabetes. Gastroenterology, 2000, 118, 986-987.	0.6	30
84	Haemochromatosis in patients with beta-thalassaemia trait. British Journal of Haematology, 2000, 111, 908-914.	1.2	19
85	Inherited HFE-unrelated hemochromatosis in italian families. Hepatology, 1999, 29, 1563-1564.	3.6	54
86	High prevalence of the His63Asp HFE mutation in italian patients with porphyria cutanea tarda. Hepatology, 1998, 27, 181-184.	3.6	195
87	Hepatic iron overload in patients with chronic viral hepatitis: Role of HFE gene mutations. Hepatology, 1998, 28, 1105-1109.	3.6	122
88	Heterogeneity of hemochromatosis in Italyâ˜†â˜†â˜†. Gastroenterology, 1998, 114, 996-1002.	0.6	227
89	HCV genotypes in Northern Italy: a survey of 1368 histologically proven chronic hepatitis C patients. Journal of Hepatology, 1998, 29, 701-706.	1.8	74
90	Liver iron influences the response to interferon alpha therapy in chronic hepatitis C. European Journal of Gastroenterology and Hepatology, 1997, 9, 497-503.	0.8	69

#	Article	IF	Citations
91	Genetic hemochromatosis in Italian patients with prophyria cutanea tarda: possible explanation for iron overload. Journal of Hepatology, 1996, 24, 564-569.	1.8	47
92	Iron stores, response to Î±â€interferon therapy, and effects of iron depletion in chronic hepatitis C. Liver, 1996, 16, 248-254.	0.1	103
93	Liver iron concentration in chronic viral hepatitis: a study of 98 patients. European Journal of Gastroenterology and Hepatology, 1995, 12, 1203-1208.	0.8	63
94	Portal hypertension and iron depletion in patients with genetic hemochromatosis. Hepatology, 1995, 22, 1127-1131.	3.6	42
95	Breakthrough during recombinant interferon alfa therapy in patients with chronic Hepatitis C virus infection: Prevalence, etiology, and management. Hepatology, 1995, 21, 645-649.	3.6	41
96	Prognostic factors for hepatocellular carcinoma in genetic hemochromatosis. Hepatology, 1994, 20, 1426-1431.	3.6	116
97	Time course of circulatory and humoral effects of rapid total paracentesis in cirrhotic patients with tense, refractory ascites. Gastroenterology, 1994, 106, 709-719.	0.6	108
98	Comparable frequency of hepatocellular carcinoma in cirrhosis of different aetiology. European Journal of Gastroenterology and Hepatology, 1994, 6, 1129-1134.	0.8	11
99	Linkage analysis of 6p21 polymorphic markers and the hereditary hemochromatosis: localization of the gene centromeric to HLA-F. Human Molecular Genetics, 1993, 2, 571-576.	1.4	40
100	Preclinical hypogonadism in genetic hemochromatosis in the early stage of the disease: evidence of hypothalamic dysfunction. Journal of Endocrinological Investigation, 1992, 15, 423-428.	1.8	27
101	Surival and prognostic factors in 212 Italian patients with genetic hemochromatosis. Hepatology, 1992, 15, 655-659.	3.6	208
102	Saturability of hepatic iron deposits in genetic hemochromatosis. Hepatology, 1992, 16, 956-959.	3.6	22
103	Hepatitis C virus and porphyria cutanea tarda: Evidence of a strong association. Hepatology, 1992, 16, 1322-1326.	3.6	298
104	Immunohistochemical evidence for a lack of ferritin in duodenal absorptive epithelial cells in idiopathic hemochromatosis. Gastroenterology, 1989, 96, 1071-1078.	0.6	72
105	Association of Hereditary Spherocytosis and Idiopathic Hemochromatosis: A Synergistic Effect in Determining Iron Overload. American Journal of Clinical Pathology, 1986, 86, 645-649.	0.4	35
106	Clinical, biochemical and histological features of primary haemochromatosis: a report of 67 cases. Liver, 1986, 6, 310-315.	0.1	24
107	Iron overload in subjects with beta-thalassaemia trait: role of idiopathic haemochromatosis gene. British Journal of Haematology, 1985, 61, 487-490.	1.2	33
108	Serum type III procollagen peptide in alcoholic liver disease and idiopathic hemochromatosis: Its relationship to hepatic fibrosis, activity of the disease and iron overload. Hepatology, 1985, 5, 475-479.	3.6	49